164 related articles for article (PubMed ID: 26722317)
1. Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients.
Yamamoto N; Kozaki A; Hartomo TB; Yanai T; Hasegawa D; Kawasaki K; Kosaka Y; Matsuo M; Hirase S; Mori T; Hayakawa A; Iijima K; Nishio H; Nishimura N
Oncol Lett; 2015 Nov; 10(5):3228-3232. PubMed ID: 26722317
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease monitoring in neuroblastoma patients based on the expression of a set of real-time RT-PCR markers in tumor-initiating cells.
Hartomo TB; Kozaki A; Hasegawa D; Van Huyen Pham T; Yamamoto N; Saitoh A; Ishida T; Kawasaki K; Kosaka Y; Ohashi H; Yamamoto T; Morikawa S; Hirase S; Kubokawa I; Mori T; Yanai T; Hayakawa A; Takeshima Y; Iijima K; Matsuo M; Nishio H; Nishimura N
Oncol Rep; 2013 Apr; 29(4):1629-36. PubMed ID: 23417100
[TBL] [Abstract][Full Text] [Related]
3. Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers.
Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Yalcin B; Dee R; van Noesel MM; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
Clin Chem; 2009 Jul; 55(7):1316-26. PubMed ID: 19460840
[TBL] [Abstract][Full Text] [Related]
4. Minimal Residual Disease Detected by the 7NB-mRNAs ddPCR Assay Is Associated with Disease Progression in High-Risk Neuroblastoma Patients: A Prospective Multicenter Observational Study in Japan.
Nishimura N; Ishida T; Yokota I; Matsumoto K; Shichino H; Fujisaki H; Sarashina T; Kamijo T; Takimoto T; Iehara T; Tajiri T; On Behalf Of The Jccg Neuroblastoma Committee
Biology (Basel); 2023 Oct; 12(10):. PubMed ID: 37887060
[TBL] [Abstract][Full Text] [Related]
5. Early detection of tumor relapse/regrowth by consecutive minimal residual disease monitoring in high-risk neuroblastoma patients.
Hirase S; Saitoh A; Hartomo TB; Kozaki A; Yanai T; Hasegawa D; Kawasaki K; Kosaka Y; Matsuo M; Yamamoto N; Mori T; Hayakawa A; Iijima K; Nishio H; Nishimura N
Oncol Lett; 2016 Aug; 12(2):1119-1123. PubMed ID: 27446404
[TBL] [Abstract][Full Text] [Related]
6. Limited correlation between tumor markers and minimal residual disease detected by seven neuroblastoma-associated mRNAs in high-risk neuroblastoma patients.
Uemura S; Lin KS; Mon Thwin KK; Nakatani N; Ishida T; Yamamoto N; Tamura A; Saito A; Mori T; Hasegawa D; Kosaka Y; Nino N; Nagano C; Takafuji S; Iijima K; Nishimura N
Mol Clin Oncol; 2021 Jul; 15(1):137. PubMed ID: 34055352
[TBL] [Abstract][Full Text] [Related]
7. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.
Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Kleijn I; Dee R; Hooft L; van Noesel MM; Bierings M; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
J Clin Oncol; 2008 Nov; 26(33):5443-9. PubMed ID: 18838715
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease in high-risk neuroblastoma shows a dynamic and disease burden-dependent correlation between bone marrow and peripheral blood.
Lin KS; Uemura S; Thwin KKM; Nakatani N; Ishida T; Yamamoto N; Tamura A; Saito A; Mori T; Hasegawa D; Kosaka Y; Nino N; Nagano C; Takafuji S; Iijima K; Nishimura N
Transl Oncol; 2021 Aug; 14(8):101019. PubMed ID: 33993097
[TBL] [Abstract][Full Text] [Related]
9. Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma.
Cheung IY; Feng Y; Gerald W; Cheung NK
Clin Cancer Res; 2008 Nov; 14(21):7020-7. PubMed ID: 18980998
[TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ
Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681
[TBL] [Abstract][Full Text] [Related]
11. RT-PCR demonstrates superior sensitivity and specificity in detecting the five neuroblastoma genes compared to the flow cytometry method for measurable residual disease.
Tian X; Li H; Luo T; Mao J; Yuan X; Gao Q; Xiao J; Qian S; Zou R; Chen K; Zhu C; Yi C; He X
Transl Pediatr; 2023 Dec; 12(12):2232-2246. PubMed ID: 38197110
[TBL] [Abstract][Full Text] [Related]
12. Higher levels of minimal residual disease in peripheral blood than bone marrow before 1st and 2nd relapse/regrowth in a patient with high‑risk neuroblastoma: A case report.
Inoue S; Win KHN; Mon CY; Fujikawa T; Hyodo S; Uemura S; Ishida T; Mori T; Hasegawa D; Kosaka Y; Nishimura A; Nakatani N; Nino N; Tamura A; Yamamoto N; Nozu K; Nishimura N
Oncol Lett; 2023 Sep; 26(3):369. PubMed ID: 37559575
[TBL] [Abstract][Full Text] [Related]
13. Distinct Expression Profiles of Neuroblastoma-Associated mRNAs in Peripheral Blood and Bone Marrow of Non-High-Risk and High-Risk Neuroblastoma Patients.
Nakatani N; Win KHN; Mon CY; Fujikawa T; Uemura S; Saito A; Ishida T; Mori T; Hasegawa D; Kosaka Y; Inoue S; Nishimura A; Nino N; Tamura A; Yamamoto N; Nozu K; Nishimura N
Biology (Basel); 2024 May; 13(5):. PubMed ID: 38785826
[TBL] [Abstract][Full Text] [Related]
14. Specific and Sensitive Detection of Neuroblastoma mRNA Markers by Multiplex RT-qPCR.
van Zogchel LMJ; Zappeij-Kannegieter L; Javadi A; Lugtigheid M; Gelineau NU; Lak NSM; Zwijnenburg DA; Koster J; Stutterheim J; van der Schoot CE; Tytgat GAM
Cancers (Basel); 2021 Jan; 13(1):. PubMed ID: 33466359
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.
Zeijlemaker W; Kelder A; Oussoren-Brockhoff YJ; Scholten WJ; Snel AN; Veldhuizen D; Cloos J; Ossenkoppele GJ; Schuurhuis GJ
Leukemia; 2016 Mar; 30(3):708-15. PubMed ID: 26373238
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma.
Stutterheim J; Zappeij-Kannegieter L; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
Eur J Cancer; 2011 May; 47(8):1193-202. PubMed ID: 21429738
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of Minimal Residual Disease in Neuroblastoma Patients.
Uemura S; Ishida T; Thwin KKM; Yamamoto N; Tamura A; Kishimoto K; Hasegawa D; Kosaka Y; Nino N; Lin KS; Takafuji S; Mori T; Iijima K; Nishimura N
Front Oncol; 2019; 9():455. PubMed ID: 31214500
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease detected by droplet digital PCR in peripheral blood stem cell grafts has a prognostic impact on high-risk neuroblastoma patients.
Nino N; Ishida T; Nakatani N; Lin KS; Win KHN; Mon CY; Nishimura A; Inoue S; Tamura A; Yamamoto N; Uemura S; Saito A; Mori T; Hasegawa D; Kosaka Y; Nozu K; Nishimura N
Heliyon; 2022 Oct; 8(10):e10978. PubMed ID: 36276741
[TBL] [Abstract][Full Text] [Related]
19. The expression of PHOX2B in bone marrow and peripheral blood predicts adverse clinical outcome in non-high-risk neuroblastoma.
Fan H; Xing T; Hong H; Duan C; Zhao W; Zhao Q; Wang X; Huang C; Zhu S; Jin M; Su Y; Gao C; Ma X
Pediatr Hematol Oncol; 2022 May; 39(4):343-356. PubMed ID: 34752187
[TBL] [Abstract][Full Text] [Related]
20. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.
Yáñez Y; Hervás D; Grau E; Oltra S; Pérez G; Palanca S; Bermúdez M; Márquez C; Cañete A; Castel V
J Cancer Res Clin Oncol; 2016 Mar; 142(3):573-80. PubMed ID: 26498952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
